We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Amgen (Nasdaq: AMGN) and Abgenix, Inc. (Nasdaq: ABGX) today announced that Amgen has completed the Biologic License Application (BLA) submission with the U.S. Food and Drug Administration (FDA...
FREMONT, Calif., March 29 /PRNewswire-FirstCall/ -- At a special meeting held today, stockholders of Abgenix, Inc. (NASDAQ:ABGX) overwhelmingly approved the acquisition of Abgenix by Amgen...
FREMONT, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Abgenix, Inc. (NASDAQ:ABGX) will announce financial results for the fourth quarter and full year of 2005 on Tuesday, February 21, 2006, after...
FREMONT, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Abgenix, Inc. (NASDAQ:ABGX) will present at the 24th Annual JPMorgan Healthcare Conference on Monday, January 9, 2006 at 2:00 p.m. (PT). Bill...
Provides Amgen With Full Ownership of Panitumumab and Eliminates a Denosumab Royalty THOUSAND OAKS, Calif. and FREMONT, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Amgen (NASDAQ:AMGN), the world's...
FREMONT, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Abgenix, Inc. (NASDAQ:ABGX) announced today the appointment of Jeffrey H. Knapp to the newly created position of Senior Vice President of Sales...
First EGFr Inhibitor to Demonstrate Improvement in Progression-Free Survival as Monotherapy for Metastatic Colorectal Cancer THOUSAND OAKS, Calif. and FREMONT, Calif., Nov. 3...
First EGFr Inhibitor to Demonstrate Improvement in Progression-Free Survival as Monotherapy for Metastatic Colorectal Cancer ? Amgen (Nasdaq:AMGN) and Abgenix, Inc. (Nasdaq:ABGX...
THOUSAND OAKS, Calif. and FREMONT, Calif., Nov. 3 /PRNewswire-FirstCall/ -- -Amgen (NASDAQ:AMGN) and Abgenix, Inc. (NASDAQ:ABGX) will host a joint conference call on November 3 at 8:00 a.m...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions